Home Cart Sign in  
Chemical Structure| 2138299-29-1 Chemical Structure| 2138299-29-1

Structure of STING agonist-3
CAS No.: 2138299-29-1

Chemical Structure| 2138299-29-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

STING agonist-3 is a selective small-molecule STING agonist which has durable anti-tumor effect and tremendous potential to improve treatment of cancer.

Synonyms: diABZI STING Agonist-3; diABZI-3; VBN99291

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of STING agonist-3

CAS No. :2138299-29-1
Formula : C37H42N12O6
M.W : 750.81
SMILES Code : O=C(C1=CC(OCCCO)=C2C(N=C(NC(C3=CC(C)=NN3CC)=O)N2C/C=C/CN4C5=CC=C(C(N)=O)C=C5N=C4NC(C6=CC(C)=NN6CC)=O)=C1)N
Synonyms :
diABZI STING Agonist-3; diABZI-3; VBN99291
MDL No. :MFCD31814375

Safety of STING agonist-3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 cells 2.5 µM Assess migration capability of THP-1 cells PMC9605868
H1299 cells 50 μM 24 hours Inhibits HSP accumulation, thereby suppressing thermotolerance PMC9473576
HEK293T cells 2.5 µM 6 hours To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC9605868
HeLa cells 2.5 µM 2 hours To evaluate the ability of BSA–RuII(CO)2 complex to release CO in HeLa cells, results showed a significant increase in intracellular fluorescence indicating CO release. PMC9605868
CisMPNST cells 10 μM 8, 18, 24, or 48 hours To evaluate STING pathway activation, results showed increased expression of phosphorylated IRF (p-IRF) and p–NF-ĸB after 8 hours, indicating STING pathway activation PMC11093615
HTS-Luc MPNST cells 10 μM 8, 18, 24, or 48 hours To evaluate STING pathway activation, results showed increased expression of phosphorylated IRF (p-IRF) and p–NF-ĸB after 8 hours, indicating STING pathway activation PMC11093615
CisMPNST cells 10 μM 8, 18, 24, or 48 hours To evaluate STING pathway activation, results showed increased expression of phosphorylated IRF (p-IRF) and p–NF-ĸB after 8 hours, indicating STING pathway activation PMC11093615
HTS-Luc MPNST cells 10 μM 8, 18, 24, or 48 hours To evaluate STING pathway activation, results showed increased expression of phosphorylated IRF (p-IRF) and p–NF-ĸB after 8 hours, indicating STING pathway activation PMC11093615
FLO-1 cells 50 μM 24 hours Evaluate eprenetapopt-induced cell death, results showed ferroptosis inhibitors could reverse cell death PMC9473576
OACM5.1 cells 50 μM 12 hours Evaluate the effect of eprenetapopt on GSH levels, results showed decreased GSH levels PMC9473576
HEK293T cells 24 hours To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC7958565

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CisNP mouse model 50 μg (intratumoral) or 50 mg/kg (intraperitoneal) Intratumoral or intraperitoneal Intratumoral: days 1, 4, 7; intraperitoneal: single injection, duration 12 days To evaluate the effect of STING agonist on MPNST growth, results showed that STING agonist treatment significantly slowed tumor growth and promoted T cell infiltration PMC11093615
NSG mice FLO-1 LM xenograft model 100 mg/kg intraperitoneal injection Daily for 35 days Evaluate the effect of combining eprenetapopt with serine and glycine dietary restriction, results showed combination therapy significantly inhibited tumor growth PMC9473576

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.33mL

0.27mL

0.13mL

6.66mL

1.33mL

0.67mL

13.32mL

2.66mL

1.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories